Home22UA • FRA
add
BioNTech SE - ADR
Previous close
€90.95
Day range
€92.40 - €92.40
Year range
€69.70 - €124.60
Market cap
24.05B USD
Avg Volume
811.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.19B | -19.54% |
Operating expense | 816.80M | 15.32% |
Net income | 259.50M | -43.33% |
Net profit margin | 21.81 | -29.55% |
Earnings per share | 1.08 | -43.16% |
EBITDA | 295.10M | -52.80% |
Effective tax rate | 13.84% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 16.78B | 1.42% |
Total assets | 22.53B | -2.07% |
Total liabilities | 3.12B | 12.98% |
Total equity | 19.41B | — |
Shares outstanding | 240.28M | — |
Price to book | 1.13 | — |
Return on assets | 1.44% | — |
Return on capital | 1.66% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 259.50M | -43.33% |
Cash from operations | -463.30M | -154.45% |
Cash from investing | 606.70M | 122.51% |
Cash from financing | -7.30M | 43.41% |
Net change in cash | 137.30M | 107.49% |
Free cash flow | -174.31M | -130.73% |
About
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
CEO
Founded
2008
Website
Employees
6,133
